Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective

NIH-supported clinical trial addresses important barrier to opioid use disorder treatment [] [View as webpage / Share]( [NIH/NIDA logo] NEWS [Rear view of two men wearing construction uniforms sitting down for a lunch break at a building renovation site.] Faster approach for starting extended-release naltrexone to treat opioid use disorder shown effective Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking treatment is more effective than the standard treatment method of starting within 10-15 days, but requires closer medical supervision, according to [results from a clinical trial]( supported by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). Published in JAMA Network Open, the findings suggest that this rapid treatment protocol could make XR-naltrexone more viable as a treatment option for opioid use disorder, which continues to take lives at an alarming rate. [View Press Release]( Stay Connected [facebook]([twitter]([linkedin]([youtube]( --------------------------------------------------------------- View topics of interest, update your subscriptions, modify your password or email address, alter frequency of bulletins, or stop subscriptions at any time on your [Subscriber Preferences Page](. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit [subscriberhelp.govdelivery.com](. This service is provided to you at no charge by [National Institute on Drug Abuse](. --------------------------------------------------------------- This email was sent to {EMAIL} using govDelivery Communications Cloud on behalf of National Institutes of Health: National Institute on Drug Abuse · 3WFN MSC 6024 · 16071 Industrial Dr ·Dock 11 · Gaithersburg, MD 20877 [GovDelivery logo](